INFERTILITY DRUGS MARKET ANALYSIS

Infertility Drugs Market, By Drug Type (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), By Route of Administration (Oral and Parenteral), By Gender (Male and Female), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In May 2024, Turkiye requested India for Gonadotropin drugs that are used in obstetrics and gynecology due to their huge demand for in-vitro fertilization (IVF) in the country.
In February 2024, Lupin Limited introduced Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe in the U.S., following approval from the U.S. Food and Drug Administration (FDA). This product is a generic equivalent of Organon USA LLC's reference listed drug (RLD), Ganirelix Acetate Injection, and is aimed at treating infertility.
In February 2023, Russia commenced domestic production of recombinant follicle-stimulating hormone and two other IVF medications. It also plans include using biotechnology to manufacture human chorionic gonadotropin hormone, aiming to address raw material shortages.
In August 2022, the U.S. FDA approved Akorn Operating Company's cetrorelix acetate for injection, a generic version of Cetrotide. This approval allows the medication to prevent early luteinizing hormone surges in females undergoing controlled ovarian stimulation.

Infertility Drugs Market Report Snapshots